Drugs / PEMLIMOGENE MEROLISBAC
PEMLIMOGENE MEROLISBAC
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT02592967 | Dec 2015 → Aug 2018 | non-small cell lung carcinoma | Janssen Research & Development, LLC | Terminated | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT03371381 | Jan → Oct 2018 | lung adenocarcinoma | Janssen Research & Development, LLC | Terminated | No outcome recorded |
Evidence & citations 6 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | PEMLIMOGENE MEROLISBAC | ChEMBL registry synonym — accepted as the source's own label CHEMBL4297241 ↗ |
| Known as | ADU-214 | ChEMBL registry synonym — accepted as the source's own label CHEMBL4297241 ↗ |
| Known as | JNJ-64041757 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02592967 ↗ |
| Known as | Pemlimogen merolisbac | ChEMBL registry synonym — accepted as the source's own label CHEMBL4297241 ↗ |
| Modality | Other / unclassified | “a live attenuated double deleted (LADD) Listeria monocytogenes (bacteria in which two virulence genes, which encode molecules that help cause disease, have been removed)” NCT02592967 ↗ |
| Route | Intravenous | “JNJ-64041757 will be administered IV” NCT02592967 ↗ |